Hunan Hansen Pharmaceutical Co. Ltd. (002412) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hunan Hansen Pharmaceutical Co. Ltd.

Why is Hunan Hansen Pharmaceutical Co. Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 5.18% and Operating profit at 18.80% over the last 5 years

Positive results in Mar 26

OPERATING CASH FLOW(Y) Highest at CNY 188.12 MM
NET PROFIT(HY) At CNY 153.11 MM has Grown at 53.5%
DEBT-EQUITY RATIO (HY) Lowest at -21.46 %

With ROE of 9.23%, it has a fair valuation with a 1.27 Price to Book Value

Over the past year, while the stock has generated a return of 0.67%, its profits have risen by 30.5% ; the PEG ratio of the company is 0.5

Underperformed the market in the last 1 year

The stock has generated a return of 0.67% in the last 1 year, much lower than market (China Shanghai Composite) returns of 21.43%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Hunan Hansen Pharmaceutical Co. Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Hunan Hansen Pharmaceutical Co. Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Hunan Hansen Pharmaceutical Co. Ltd.

-3.4%

0.33

32.97%

China Shanghai Composite

21.43%

1.55

13.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.18%

EBIT Growth (5y)

18.80%

EBIT to Interest (avg)

45.43

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.15

Sales to Capital Employed (avg)

0.44

Tax Ratio

13.46%

Dividend Payout Ratio

76.20%

Pledged Shares

Institutional Holding

ROCE (avg)

8.69%

ROE (avg)

9.10%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.27

EV to EBIT

11.76

EV to EBITDA

10.73

EV to Capital Employed

1.34

EV to Sales

2.48

PEG Ratio

0.45

Dividend Yield

ROCE (Latest)

11.43%

ROE (Latest)

9.23%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 188.12 MM

NET PROFIT(HY)

At CNY 153.11 MM has Grown at 53.5%

DEBT-EQUITY RATIO (HY)

Lowest at -21.46 %

RAW MATERIAL COST(Y)

Fallen by -5.55% (YoY

CASH AND EQV(HY)

Highest at CNY 1,154.38 MM

-2What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.09 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.09 times

Here's what is working for Hunan Hansen Pharmaceutical Co. Ltd.

Operating Cash Flow

Highest at CNY 188.12 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Profit

At CNY 153.11 MM has Grown at 53.5%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at -21.46 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Cash and Eqv

Highest at CNY 1,154.38 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -5.55% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hunan Hansen Pharmaceutical Co. Ltd.

Inventory Turnover Ratio

Lowest at 1.09 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.09 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio